Clinical trial
A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study Investigating Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)
NCT03697265 is registered in ClinicalTrials.gov with Asarina Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study Investigating Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)
- Lead sponsor
- Asarina Pharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 20, 2018
- Completion date
- October 23, 2020
- Enrollment
- 475 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.